DOCSLIB.ORG

The Effect of Drug Packaging on Patients' Compliance with Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Drug Packaging on Patients' Compliance with Treatment The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China Li Qingjun,l 4 Duan Jihui,2A Tang Laiyi,34 Zhang Xiangjun,4 Liang Jun,4 A. Hay,5 S. Shires,5 & V. Navaratnam6 A study conducted in 1994 showed that the use of blister packs containing antimalarial drugs significantly increased patients' compliance, compared with traditional means of dispensing drugs in a paper envelope. The present study assessed patients' compliance and compared the difference between 3-day chloroquine and 8-day primaquine courses of treatment for vivax malaria. The level of real compliance was determined bymarking the drugs with phenobarbital, and measuring its level in the blood following treatrnent. The results show that blisterpackaging significantly improvedpatients' compliance (P <0.001) over traditional means of dispensing antimalarial drugs; there was no difference in treatment compliance between 3-day and 8-day courses when the drugs were in blister packs. However, with ordinary packaging the treatment compliance rate for an 8-day course was significantly less than for a 3-day course (P < 0.05). Introduction from the container in a paper envelope or small pa- Hunan Province in south-central China comprises 14 per bag, and given to the patient without any identi- prefectures and 125 counties with a population of 64 fication of the drugs or written directions on their million. Since the start of the malaria control pro- use. The doctor's or health worker's oral instructions gramme in this province in the 1950s, there have to the patient on the number of tablets to be taken been three Plasmodiuim vivax malaria outbreaks and for how many days are brief and do not include with annual incidences of 1560 per 100000 in 1955, any advice or health education. Treatment is often 1690 per 100000 in 1962, and 1323 per 100000 in incomplete due to its discontinuation once the symp- 1971. Despite a comprehensive malaria control pro- toms have disappeared, or to disintegration or loss of gramme, the incidence since 1986 has risen and, for the tablets. Sometimes patients take an excessive counties in the south and south-west of the proNince, dose so as not to risk loss of the drug, and can expe- is five times higher than the provincial average. rience unpleasant side-effects. Chloroquine and primaquine are produced in Over 20 years ago, compliance was assured by China for the treatment of P. vivax malaria, and are delivering drugs on a daily basis to patients with generally dispensed by health workers from 1000- direct observation of therapy. While clearly effec- tablet bottles or tins. The current treatment regimen tive. this was unsustainable owing to the need for for adults is 4 chloroquine tablets (each containina large numbers of health workers. To improve com- 0.25mg chloroquine phosphate) on day 1, 3 tablets pliance and use of antimalarial drugs, a pilot inter- on days 2 and 3, and 3 tablets of 13.2mg primaquine vention study was undertaken to determine the daily from day 1 to 8. The curative dosage of each effects of new packaging of drugs and written is a instructions on compliance. drug dispensed by health worker or pharmacist The specific objectives of the study were as follows: IDirector. 2 Professor of Parasitology. - To compare the compliance of patients in 3Professor of Epidemiology. completing a full course of antimalarial treat- 4Health and Epidemic Prevention Station Hunan Province, ment; a control group received medication in pa- Changsha, Hunan, China. per envelopes and a second group were given the 5 Division of Clinical Sciences, School of Medicine, Old Medical improved packaging with simple, written instruc- School, University of Leeds, Leeds, England. tions on their use. e Director, Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia. - To determine the possible reasons for non- Requests for reprints should be sent to Dr M. Gomes at the compliance in both groups and whether they address shown on p. 9. were related to the type of packaging and instruc- Reprnt No. 5847 tions on use. Builetin of the World Health Organization, 1998, 76 (Suppl. 1): 21-27 0 World Health Organlzation 1998 21 U QingJun et al. - To evaluate the impact of the new packaging and Hunan, the disease is introduced, causing epidemics of providing simple, written instructions with the of imported malaria. medication. Patients. The patients in the study were consenting - To determine the difference between reported adults (aged >15 years) with confirmed, slide- compliance (Phase-I study, based on only pa- positive vivax malaria; they were ambulatory, had tients' reports) and true compliance (Phase-Il no major clinical symptoms requiring hospitaliza- study, including use of a pharmacological marker tion, and had not received any malaria treatment inserted with each antimalarial tablet). during the previous 6 months. On selection at one of the clinic sites, a patient was randomly assigned either to the new drug packaging group or to the Materials and methods control group prior to receiving medication. Upon entry to the study, basic data were recorded on each Blister packs. The tablets of chloroquine and patient, including age, sex, occupation, suspected primaquine for the study were provided in two onse't of infection, clinical symptoms, laboratory packs, one for chloroquine (with daily doses sepa- test results, and date and time of treatment. When rated for three consecutive days) and the second for the drug regimen was completed in phase I and primaquine (with daily doses of 3 tablets for a total phase II, information was solicited on when the first of 8 days). The number 8, according to Chinese be- and last doses of the drug were taken, the total liefs, brings good luck and it was considered that a number of tablets taken, and on compliance and course of primaquine over 8 days would enhance non-compliance. compliance more than one for 14 days. Detailed oral instructions were given to the patients on the correct Phase J. As mentioned above, this phase was carried dosage and the need to complete the treatment. out in five counties of Hunan Province. Patients in The new blister pack was hermetically sealed, the control group were prescribed medication with separately for each day's supply of tablets, with the oral instructions on their use; the antimalarial tablets name of the drug on the back of the pack. The blister (chloroquine and primaquine) were put into a paper packs were inserted into boxes, with the drug name envelope and given to the patients. Patients in the on the front and dosage directions and precautions intervention group were prescribed medication with on the back; clear instructions were given on a leaflet identical oral instructions; the antimalarial tablets inside the box. Each pack measured 8 X 5.5cm and were given in two separate blister packs, marked contained 10 tablets of chloroquine for use over 3 with appropriate daily dosages and containing de- days, or 24 tablets of primaquine for 8 days. tailed written instructions. The advice given by the doctor to both the control and the intervention Study sites. For the phase I study, which was con- groups was the same regarding malaria and treat- ducted during the malaria season in 1994, the Health ment. However, each patient in the intervention and Epidemic Prevention Stations in five counties of group was asked to open the blister pack and read Hunan Province were selected as the study site. In the instructions for treatment found inside. When phase II, the Health and Epidemic Prevention they had finished reading the instructions, they were Stations in seven counties implemented the study in asked if they understood what they had just read. the malaria season from July till October 1996. The Patients in the control group were asked if they had choice of epidemic station in the counties was made understood the doctor's oral instructions. If the pa- so that a sufficient number of patients could be tient indicated a poor understanding, the instructions enrolled in the study period, which would ensure for treatment were repeated for both groups. that the study was carried out as designed. The quali- The sample size was determined using an expec- fications of the staff at these stations were high, and tation of 15% noncompliance in the control group each station had a good working relationship with and an expected 10% improvement in compliance the provincial authorities. (or 15% noncompliance) in the intervention group. During the study period, millions of people With a desired confidence level of 95%, a power of from Hunan Province migrated to Guangdong and 80%, and a ratio of 1:1 in the control and interven- Hainan Provinces where a high level of economic tion groups, the sample size was determined to be development was taking place. Most workers were 318 persons - 159 in the control group and 159 in engaged in mining and road and house constructions the intervention group. The choice of 15% noncom- in areas of high malaria endemicity. Malaria is com- pliance and an expected improvement in a compli- mon among the migrant. nonimmune populations ance of 10% was conservative as was also the sample and when these persons return to their homes in size. 22 WHO Bulletin OMS. Vol 76 (Suppl. 1) 1998 Effect of drug packaging on compliance with antimalarial treatment On day 9 (after the start of treatment), dav 1 followed by 3 capsules on each of days 2 and 3) each patient was either visited at home by a doctor in and 24 tablets total of primaquine over 8 days (3 the study team or patients returned to the Epidemic tablets daily for 8 days).
Load more

Recommended publications
  • Supplemental Information
    Supplemental information Table S1 Sample information for the 36 Bactrocera minax populations and 8 Bactrocera tsuneonis populations used in this study Species Collection site Code Latitude Longitude Accession number B. minax Shimen County, Changde SM 29.6536°N 111.0646°E MK121987 - City, Hunan Province MK122016 Hongjiang County, HJ 27.2104°N 109.7884°E MK122052 - Huaihua City, Hunan MK122111 Province 27.2208°N 109.7694°E MK122112 - MK122144 Jingzhou Miao and Dong JZ 26.6774°N 109.7341°E MK122145 - Autonomous County， MK122174 Huaihua City, Hunan Province Mayang Miao MY 27.8036°N 109.8247°E MK122175 - Autonomous County, MK122204 Huaihua City, Hunan Province Luodian county, Qiannan LD 25.3426°N 106.6638°E MK124218 - Buyi and Miao MK124245 Autonomous Prefecture, Guizhou Province Dongkou County, DK 27.0806°N 110.7209°E MK122205 - Shaoyang City, Hunan MK122234 Province Shaodong County, SD 27.2478°N 111.8964°E MK122235 - Shaoyang City, Hunan MK122264 Province 27.2056°N 111.8245°E MK122265 - MK122284 Xinning County, XN 26.4652°N 110.7256°E MK122022 - Shaoyang City,Hunan MK122051 Province 26.5387°N 110.7586°E MK122285 - MK122298 Baojing County, Xiangxi BJ 28.6154°N 109.4081°E MK122299 - Tujia and Miao MK122328 Autonomous Prefecture, Hunan Province 28.2802°N 109.4581°E MK122329 - MK122358 Guzhang County, GZ 28.6171°N 109.9508°E MK122359 - Xiangxi Tujia and Miao MK122388 Autonomous Prefecture, Hunan Province Luxi County, Xiangxi LX 28.2341°N 110.0571°E MK122389 - Tujia and Miao MK122407 Autonomous Prefecture, Hunan Province Yongshun County, YS 29.0023°N
    [Show full text]
  • White Paper MIGRATION SAFE PHARMACEUTICAL LABELS IMPROVE PATIENT SAFETY Table of Contents
    White Paper MIGRATION SAFE PHARMACEUTICAL LABELS IMPROVE PATIENT SAFETY Table of contents Executive summary ................................................................................................... 3 2. Drug packaging helps ensure patient safety ............................................................. 4 3. Packaging, a multi-faceted performer ...................................................................... 4 3.1. Primary packaging ...................................................................................... 5 3.2. Secondary packaging ................................................................................. 5 3.3. Tertiary packaging ...................................................................................... 5 3.4. Packaging type matters ................................................................................ 5 4. The future of pharma packaging is plastics ............................................................... 6 5. Control and complexity: Navigating packaging development ...................................... 7 5.1. Drug companies carefully control pharmaceutical packaging .............................. 8 5.2. Switch from glass to plastic containers ........................................................... 9 5.2.1 Low-quality or incorrectly selected labels can pose extractable and leaching risks ............................................................. 9 5.2.2 Migration studies help increase drug safety ........................................... 9 6. Test and test
    [Show full text]
  • Pharmaceutical Packaging
    INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS CLICK TO VIEW Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom Research, Related Studies, Corporate Use License 8 Pharmaceutical Packaging US Industry Study with Forecasts for 2012 & 2017 Study #2341 | May 2008 | $4700 | 319 pages The Freedonia Group 767 Beta Drive www.freedoniagroup.com Cleveland, OH • 44143-2326 • USA Toll Free US Tel: 800.927.5900 or +1 440.684.9600 Fax: +1 440.646.0484 E-mail: [email protected] Study #2341 May 2008 Pharmaceutical Packaging $4700 319 Pages US Industry Study with Forecasts for 2012 & 2017 PRODUCT OVERVIEW Plastic Pharmaceutical Closures ....................... 164 Child-Resistant Plastic Closures ................... 166 General ............................................................. 67 Standard Plastic Closures ............................ 169 Table of Contents Pharmaceutical Packaging Product Groups ............... 69 Flip-Top Plastic Closures ............................. 170 Unit Dose Packaging ............................................ 74 Plastic Dispensing Closures ......................... 170 Anti-Counterfeit Drug Packaging............................ 75 Disc Closures ......................................... 171 EXECUTIVE SUMMARY Historical Demand Patterns ................................... 77 Pump-Type Closures ............................... 171 US Trade ...........................................................
    [Show full text]
  • Building Better Manufacturing Facilities
    APRIL 2020 Volume 32 Number 4 Building Better Manufacturing Facilities Development Accelerating Vaccine Development Optimizing Drug Delivery Manufacturing HPAPI Tabletting Safety Quality/Regulations Supplier Oversight Analytics Cleaning Validation Operations Cold-Chain Packaging Outsourcing Continuous Bioprocessing Peer-Review Research Identifying Impurity in Topical Gel 9th - 11th September | Philadelphia GL-CM-2000006 AD_04.20 Pharma Technology Europe_CPhI North Philadelphia_LOGOS_03.indd 1 16/3/20 11:39 April 2020 Pharmaceutical Technology Europe is the authoritative Advancing Development & Manufacturing source of peer-reviewed research and expert analyses for scientists, engineers, and managers engaged in process PharmTech.com development, manufacturing, formulation and drug delivery, API synthesis, analytical technology and testing, packaging, IT, outsourcing, and regulatory compliance Cover: nasir1164 - Stock.adobe.com in the pharmaceutical and biotechnology industries. Art direction: Maria Reyes 36 16 9 26 PharmTech.com OPERATIONS Features 29 Packaging Preserves the Cold Chain COVER STORY: MANUFACTURING More sustainable and functional 9 Building Better Manufacturing Facilities cold-chain packaging protects biologics Whether refitting existing spaces or building and other temperature-sensitive drugs. new, the need for quick build times, flexibility, QUALITY/REGULATIONS and production efficiency is driving trends 33 Being Vigilant in Supplier Oversight in bio/pharma facility construction. Risk assessments, audits, and good DEVELOPMENT communication between sponsor and 13 Can Vaccine Development supplier are key elements of supplier oversight. Be Safely Accelerated? OUTSOURCING Biopharma companies responding to the 36 Biomanufacturing: Demand COVID-19 outbreak think accelerating the for Continuous Bioprocessing Increasing development of vaccines is safe. But are innovations sufficient to increase adoption? CMOs are demanding better 16 Delivering the Goods continuous bioprocessing options.
    [Show full text]
  • The Effectiveness of Field Pest Management and Culling at Harvest for Risk Mitigation of Two Fruit Flies Affecting Citrus in China
    The effectiveness of field pest management and culling at harvest for risk mitigation of two fruit flies affecting citrus in China Yulu Xia1, Jiayao He2, Hui Liu3, Fulian Xiao3, Linzuo Xiao5, Xingli Ma1, Guocai Lu2, Zhushan Lin5, Xubin Pan2,*, and Gecheng Ouyang4,* Abstract The oriental fruit fly, Bactrocera dorsalis (Hendel) (Diptera: Tephrtitidae), and the Chinese citrus fly, Bactrocera minax (Enderlein) (Diptera: Tephri- tidae), are 2 destructive citrus fruit pests in China. A field study was conducted during Sep to Oct of 2018 in Dongkou County of Hunan Province to assess (1) fruit infestations at the time of harvest under 2 management levels, and (2) the efficacy of culling at harvest (i.e., visual inspection and removal of the infested fruits) on reducing the number of infested fruits. A total of 26,400 fruits of Satsuma mandarins, Citrus unshiu (Swingle) Marcov (Rutaceae), were harvested from 2 groves with 1 representing highly managed groves, and the other representing commonly managed groves (low management). Fruit culling was conducted immediately to separate fruits into 5 groups: (1) B. minax infested fruits, (2) B. dorsalis infested fruits, (3) B. minax + B. dorsalis infested fruits, (4) suspected fruit fly infested fruits, and (5) fruit fly free fruits. Fruit dissection was conducted 4 wk later to determine the actual number of the infested fruits, and also to act as a check on the accuracy of visual inspection on the reduction of the number of infested fruits. The highly managed grove had 0.02% infested fruits vs. 2.19% in the low managed grove, a 99.09% reduction in infestation rate.
    [Show full text]
  • Food Packaging Technology
    FOOD PACKAGING TECHNOLOGY Edited by RICHARD COLES Consultant in Food Packaging, London DEREK MCDOWELL Head of Supply and Packaging Division Loughry College, Northern Ireland and MARK J. KIRWAN Consultant in Packaging Technology London Blackwell Publishing © 2003 by Blackwell Publishing Ltd Trademark Notice: Product or corporate names may be trademarks or registered Editorial Offices: trademarks, and are used only for identification 9600 Garsington Road, Oxford OX4 2DQ and explanation, without intent to infringe. Tel: +44 (0) 1865 776868 108 Cowley Road, Oxford OX4 1JF, UK First published 2003 Tel: +44 (0) 1865 791100 Blackwell Munksgaard, 1 Rosenørns Allè, Library of Congress Cataloging in P.O. Box 227, DK-1502 Copenhagen V, Publication Data Denmark A catalog record for this title is available Tel: +45 77 33 33 33 from the Library of Congress Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton South, British Library Cataloguing in Victoria 3053, Australia Publication Data Tel: +61 (0)3 9347 0300 A catalogue record for this title is available Blackwell Publishing, 10 rue Casimir from the British Library Delavigne, 75006 Paris, France ISBN 1–84127–221–3 Tel: +33 1 53 10 33 10 Originated as Sheffield Academic Press Published in the USA and Canada (only) by Set in 10.5/12pt Times CRC Press LLC by Integra Software Services Pvt Ltd, 2000 Corporate Blvd., N.W. Pondicherry, India Boca Raton, FL 33431, USA Printed and bound in Great Britain, Orders from the USA and Canada (only) to using acid-free paper by CRC Press LLC MPG Books Ltd, Bodmin, Cornwall USA and Canada only: For further information on ISBN 0–8493–9788–X Blackwell Publishing, visit our website: The right of the Author to be identified as the www.blackwellpublishing.com Author of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.
    [Show full text]
  • Drug-Device Co-Packing Solutions to Enhance Differentiation and Improve Experience
    BD DRUG-DEVICE CO-PACKING SOLUTIONS TO ENHANCE DIFFERENTIATION AND IMPROVE EXPERIENCE In this article, Janice Adkins, Associate Director, Global Marketing, BD, discusses the benefits that co-packing, the practice of providing drug preparation and delivery systems along with a medication, can bring to pharmaceutical manufacturers, clinicians and patients. A WELL-ESTABLISHED SOLUTION TO AID IN MEDICATION ADHERENCE “Providing a vetted, With medication nonadherence estimated co-packaged device at 50%,1 packaging solutions have emerged alongside a drug product as useful tools to help patients manage their can put manufacturers at therapies. Several studies have suggested an adherence benefit as a result of packaging ease that their products interventions, such as calendarised blister are being used as packages.2-6 In addition to adherence intended and help prevent packaging, some manufacturers have employed co-packing strategies to facilitate variability that may lead improved adherence to medications that are to product complaints.” co-administered. Examples include: • Kisqali® (ribociclib) and Femara® complex dosing regimens and/or (letrozole) Co-Pack for breast cancer by reconstitution requirements has spurred Novartis (Basel, Switzerland) innovation in packaging solutions as • Viekira Pak-RBV® (ombitasvir/ well. However, rather than drug-drug paritaprevir/ritonavir, dasabuvir and co-packing, as is the case with ribavirin) for hepatitis C from AbbVie co-administered oral medications, (Chicago, IL, US) parenteral medications often require • Orkambi® (lumacaftor/ivacaftor) for packaging solutions where drugs are cystic fibrosis from Vertex (Boston, provided alongside delivery devices or MA, US). other supplies to enable their preparation Janice Adkins or administration. This is most apparent Associate Director, Global Marketing Not all of these packaging configurations in areas where patients or caregivers are T: +1 201 847 4176 E: [email protected] are complex, with some involving a simple required to manipulate drug components, “box within a box” design.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Rubber Components Selection for Optimal Drug Packaging Simon
    Rubber components selection for optimal drug packaging Simon Kervyn Manager Material Development March 11th, 2019 Agenda 1. Composition of pharmaceutical rubber 2. Extractables and leachables from rubber 3. Expectations of extractables information sharing 4. Different rubber compositions to steer properties 5. Compound for gamma sterilisation 2 Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Stability and strength of a large industrial group Swiss origin, established in 1915 Revenues of approx. CHF 1,200 million Focused industrial player with two divisions: Sealing Solutions & Technical Components Listed on the SIX Swiss Exchange 3 Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Multi-industry knowhow 4 Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Datwyler Sealing Solutions – Health Care offer overview High quality components and closures for injectable drugs Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Datwyler Sealing Solutions – Health Care offer overview High quality components and closures for injectable drugs Vials Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Datwyler Sealing Solutions – Health Care offer overview High quality components and closures for injectable drugs Vials Syringes and cartridges Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com 1. Composition of Pharmaceutical Rubber 8 Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Types of elastomeric closures – Compounded material of: 1. Elastomer 2. Filler 3. Cure system 4. Pigment 5. Other ingredients Rubber components selection for optimal drug packaging, March 11th, 2019 / © Datwyler, www.datwyler.com Composition – 1.
    [Show full text]
  • Environmental Impact Assessment
    Public Disclosure Authorized ENVIRONMENTAL IMPACT ASSESSMENT FOR Public Disclosure Authorized A PROPOSED WORLD BANK LOAN FINANCED AGRICULTURAL TECHNOLOGY TRANSFER PROJECT Public Disclosure Authorized CENTER OF ENVIRONMENTAL IMPACT ASSESSMENT CHINESE ACADEMY OF ENVIRONMENTAL SCIENCES Public Disclosure Authorized AUGUST 2004 Agricultural Technology Transfer Project – Environmental Impact Assessment AGRICULTURAL TECHNOLOGY TRANSFER PROJECT ENVIRONMENTAL IMPACT ASSESSMENT TABLE OF CONTENTS 1. SUMMARY.............................................................................................................. 1 1.1. Foreword................................................................................................................... 1 1.2. Evidence of Report Compilation............................................................................... 2 1.2.1. Planning Documents.......................................................................................... 2 1.2.2. Project Documentation...................................................................................... 3 1.2.3. Assessment Standards and Grades .................................................................... 3 1.2.4. World Bank Safeguard Policy ........................................................................... 3 1.3. Scope of Assessment................................................................................................. 4 2. BRIEF PROJECT DESCRIPTION ............................................................................. 4 2.1. Project
    [Show full text]
  • Drug Stewardship Plan
    CONTRA COSTA COUNTY SAFE DRUG DISPOSAL DRUG STEWARDSHIP PLAN PROPOSAL SEPTEMBER 28,2020 Revised December 9, 2020 This submission includes information that shall not be disclosed outside the Government and shall not be duplicated, used, or disclosed - in whole or in part - for any purpose other than the evaluation hereof. Furthermore, the information contained herein, including, without limitation, Inmar, Inc.’s corporate, financial and technical data, is subject to exemption from disclosure under the Freedom of Information Act, 5 U.S.C. § 552. This document also contains confidential trade secrets and information exempt from disclosure in the public interest under Cal Civ Code § 3426.1 and Cal Gov Code § 6254. The information subject to this restriction is contained in sheets marked: “Use or Disclosure of Information Contained on This Sheet is Subject to the Restriction on the First Page of This Submittal.” SUBMITTED BY: + CONTENTS I. INTRODUCTION ...............................................................................................................................................4 II. DEFINITIONS ....................................................................................................................................................4 III. OVERVIEW ........................................................................................................................................................5 IV. PARTICIPANTS ................................................................................................................................................6
    [Show full text]
  • Leachable and Extractable Studies on Single-Use System Technologies in Commercial Scale Drug Filling Lines
    Dissertation zur Erlangung des Doktorgrades der Fakult¨atf¨urChemie und Pharmazie der Ludwig–Maximilians–Universit¨atM¨unchen Leachable and Extractable Studies on Single-Use System Technologies in commercial scale Drug Filling Lines Nicole Marion Doris Scherer aus Otjiwarongo, Namibia 2019 ii Erkl¨arung: Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Dr. Gerhard Winter betreut. Eidesstattliche Versicherung: Diese Dissertation wurde eigenst¨andigund ohne unerlaubte Hilfe erarbeitet. M¨unchen, den 19.08.2019 Nicole Scherer Dissertation eingereicht am: 05.04.2019 Erstgutachter: Prof. Dr. Gerhard Winter Zweitgutachter: Prof. Dr. Wolfgang Frieß Tag der m¨undlichen Pr¨ufung:30.04.2019 iv Danksagung In the following I want to acknowledge all supervisors, colleagues and friends who con- tributed to this work. I express my thanks in my native language German. An dieser Stelle m¨ochte ich mich bei allen Betreuern, Kollegen und Freunden bedanken die mich w¨ahrenddieser spannenden vier Jahre begleitet haben und an dem Entstehen dieser Arbeit beteiligt waren. Mein besonderer Dank gilt hierbei: Herrn Prof. Dr. Gerhard Winter f¨ursein großes Vertrauen und seine fortw¨ahrende, flexible Unterst¨utzung,ohne die diese Projekte nicht m¨oglich gewesen w¨aren. Besonderer Dank gilt auch meinem Betreuer Dr. Tobias Posset dessen unerm¨udlicher Forscherdrang meine Promotionsarbeit im industriellen Umfeld der Roche GmbH erm¨oglichte und mich in meiner Entwicklung maßgeblich gef¨orderthat. Meiner Betreuerin Dr. Klaudia Marcsekov´adanke ich ganz besonders daf¨ur,dass sie stets f¨urmich da war, mich bei jeglichen Fragen unterst¨utzthat und in allen Situationen und Lebenslagen mit Rat und Tat zur Seite Stand.
    [Show full text]